ArticleJournal of Ayurveda and integrative medicine
Geroprotection through modulation of heart rate variability, oxidative enzymes, tissue integrity, and gene expression by an Ayurvedic herbal formulation, Amalaki Rasayana.
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAging is a multifactorial process involving cumulative cellular and organ deterioration, largely due to oxidative stress and disrupted homeostasis. These changes lead to increased susceptibility to age-related diseases. Amalaki Rasayana (AR), an ayurvedic formulation from the fruit of Phyllanthus emblica, is traditionally valued for its geroprotective, rejuvenating effects and preventive healthcare.
objectiveThis study scientifically evaluates AR's impact on physiological, biochemical, and molecular markers of aging and functional decline in a rodent model.
methodsThirty-six, 10 months old, male Fischer rats, (n = 6) were randomized into normal control (NC) and Amalaki Rasayana (AR) -treated groups, and evaluated at the end of 18, 24, and 30 months of age. Comprehensive assessments including, electrocardiography, histopathology, biochemical assays, and molecular analyses were conducted to evaluate cardiac, renal, hepatic, and neural tissue health. Oxidative stress was quantified by measuring superoxide dismutase (SOD) and catalase activity. Tp53 and p21 gene expressions were quantified by qPCR and bioinformatics.
resultsOur results demonstrated pronounced age-associated degenerative changes such as neuronal loss, myocardial fibrosis, renal tubule dilation and glomerular fragmentation in NC rats. In contrast, AR-supplementation maintained heart rate variability, preserved antioxidants superoxide dismutase and catalase activities, and mitigated tissue degeneration across multiple organs. AR modulated the expression of Tp53 and p21 in cardiac and neural tissues, suggesting a role in cellular stress response and longevity pathways.
conclusionAmalaki Rasayana demonstrated potent antioxidant and cytoprotective effects in aging rats, supporting its potential as an adjuvant for healthy aging. These findings highlight AR's promise in attenuating oxidative damage and modulating gene expression, warranting further translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.